BioVie Updates on Bezisterim Parkinson's Trial and Mechanism of Action
BioVie Inc. (BIVI) hosted a virtual Key Opinion Leader event to discuss the mechanism of action of its lead candidate, Bezisterim, and its potential in addressing Parkinson's disease pathology. During the call, President and CEO Cuong Viet Do provided a critical update on the company's clinical progress. He announced that the Phase 2 clinical trial for Parkinson's disease is nearly complete, with the final patient having completed their last visit. The company is currently engaged in the study closeout process, focusing on data cleaning and analysis. A significant portion of the timeline depends on the return of biomarker data, which is essential for comprehensive evaluation. BioVie aims to have all data analyzed by the end of the current quarter, though this timeline may extend into the next quarter depending on processing speeds. Executive VP of R&D Joseph Palumbo and SVP of Operations Clarence Ahlem also participated, highlighting the scientific and operational aspects of the drug's development. The event served to inform investors and medical professionals about the therapeutic potential of Bezisterim in modifying disease progression rather than just treating symptoms.
Wire timeline
BioVie Updates on Bezisterim Parkinson's Trial and Mechanism of Action
BioVie Inc. (BIVI) hosted a virtual Key Opinion Leader event to discuss the mechanism of action of its lead candidate, Bezisterim, and its potential in addressing Parkinson's disease pathology. During the call, President and CEO Cuong Viet Do provided a critical update on the company's clinical progress. He announced that the Phase 2 clinical trial for Parkinson's disease is nearly complete, with the final patient having completed their last visit. The company is currently engaged in the study closeout process, focusing on data cleaning and analysis. A significant portion of the timeline depends on the return of biomarker data, which is essential for comprehensive evaluation. BioVie aims to have all data analyzed by the end of the current quarter, though this timeline may extend into the next quarter depending on processing speeds. Executive VP of R&D Joseph Palumbo and SVP of Operations Clarence Ahlem also participated, highlighting the scientific and operational aspects of the drug's development. The event served to inform investors and medical professionals about the therapeutic potential of Bezisterim in modifying disease progression rather than just treating symptoms.
All Articles on Seeking Alpha